Wedbush Predicts argenx’s Q2 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Equities researchers at Wedbush boosted their Q2 2025 earnings per share (EPS) estimates for argenx in a research note issued on Thursday, February 27th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $4.22 per share for the quarter, up from their prior estimate of $4.15. Wedbush has a “Outperform” rating and a $655.00 price objective on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenx’s Q3 2025 earnings at $5.17 EPS, FY2025 earnings at $18.40 EPS and FY2028 earnings at $61.66 EPS.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million.

Several other equities analysts have also issued reports on the company. Truist Financial reaffirmed a “buy” rating and set a $700.00 price target (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. William Blair reaffirmed an “outperform” rating on shares of argenx in a research note on Friday. JMP Securities upped their price target on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. HC Wainwright upped their price objective on argenx from $717.00 to $720.00 and gave the company a “buy” rating in a report on Friday. Finally, Piper Sandler upped their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $661.17.

argenx Stock Down 0.0 %

Shares of ARGX opened at $624.67 on Monday. argenx has a 12-month low of $349.86 and a 12-month high of $678.21. The firm has a market capitalization of $37.96 billion, a PE ratio of -709.85 and a beta of 0.58. The stock’s fifty day simple moving average is $642.62 and its 200-day simple moving average is $591.22.

Institutional Investors Weigh In On argenx

Several large investors have recently modified their holdings of the business. Stifel Financial Corp grew its holdings in shares of argenx by 15.3% during the third quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after buying an additional 1,170 shares in the last quarter. FMR LLC grew its holdings in shares of argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after buying an additional 1,265,486 shares in the last quarter. Simplify Asset Management Inc. grew its holdings in shares of argenx by 64.0% during the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock worth $1,311,000 after buying an additional 944 shares in the last quarter. Stephens Inc. AR bought a new position in shares of argenx during the fourth quarter worth about $310,000. Finally, Ritholtz Wealth Management grew its holdings in shares of argenx by 85.5% during the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock worth $552,000 after buying an additional 414 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.